NEW YORK (GenomeWeb) – When Greenwood Genetics Center announced last week that it is now offering Affymetrix's US Food and Drug Administration-cleared CytoScan Dx Assay to its clinicians for chromosomal microarray analysis, it became the first laboratory in the US to do so.

Though the Greenwood, SC-based center already offers a laboratory-developed test based on Affymetrix's research use only CytoScan HD product, the addition of the CytoScan Dx Assay appeals to users for multiple reasons, according to Alka Chaubey, director of the center's cytogenetics laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligences for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.